Drug-induced Death Rate
Drug-induced Death Rate - Related Videos
02:06
Inducing Brain Death in a Mouse Model Using a Balloon Catheter
0 Views •
2025
This video demonstrates the procedure for inducing brain death in a mouse model by increasing controlled intracranial pressure through a balloon catheter, mimicking natural brain death.
10:06
An Introduction to Cell Death
0 Views •
2023
Necrosis, apoptosis, and autophagic cell death are all manners in which cells can die, and these mechanisms can be induced by different stimuli, such as cell injury, low nutrient levels, or signaling proteins. Whereas necrosis is considered to be an “accidental” or unexpected form of cell death, evidence exists that apoptosis and autophagy are both programmed and “planned” by cells.In this introductory video, JoVE highlights key discoveries pertaining to cell death, including recent work done...
03:50
An Ex Vivo Technique to Induce Neuronal Death via Oligodendrocyte-Specific CD8+ T Cells
0 Views •
2025
This video demonstrates an ex vivo technique to induce brain cell death mediated through cytotoxic CD8+ T cells. Upon obtaining brain slices, activated oligodendrocyte-directed CD8+ T cells are transferred onto the slices to target the myelin sheath and oligodendrocytes. Post-incubation, the damage to myelin and neuronal death can be assessed histologically in the regions of interest.
04:47
Zebrafish Cardiomyopathy Model: Drug-Induced Cardiotoxicity
0 Views •
2023
This video describes the technique of creating a zebrafish cardiomyopathy model with minimal variations among experimental groups and in the sample, we create zebrafish cardiomyopathy model using the drug doxorubicin.
01:27
Enhancing Drug Delivery in Recurrent Glioblastoma with Laser-Induced Hyperthermia
0 Views •
2025
Begin with an anesthetized human patient diagnosed with recurrent glioblastoma, an invasive tumor characterized by tumor cell infiltration into the surrounding peritumoral region.The peritumoral region retains an intact blood-brain barrier (BBB), where tight junctions between endothelial cells restrict drug penetration.Make an incision in the scalp, create an opening in the skull, and insert a laser probe into the tumor core using MRI guidance.Deliver laser light through the probe.Tissue...
FAQs
Researchers begin with coded cause-of-death records to identify deaths attributed to drug effects. They then relate that death count to the population at risk during a specified period and report the result for defined groups or time intervals. This procedure converts individual mortality records into a standardized population measure that supports comparisons across populations and periods.
A death count alone can be misleading because populations differ in size. Dividing drug-induced deaths by the population at risk expresses mortality relative to the population exposed to the possibility of such an outcome. This adjustment makes comparisons more informative across groups or periods, rather than treating a larger population as inherently higher risk.
Age structure should be considered when populations or time periods differ meaningfully in their age composition. Researchers can account for those differences when appropriate, helping determine whether an observed rate pattern reflects drug-related mortality rather than variation in the populations’ age profiles. This improves interpretation of trends and supports more valid epidemiological comparisons.
The measure can place medication- and substance-related mortality within a common epidemiological framework. Its scope is useful for examining risks attributed to drug effects without limiting attention to one type of exposure. In cancer research, that broader view can include treatment-related safety concerns, opioid exposure, and supportive-care medications when interpreting mortality patterns.
A basic workflow consists of selecting the relevant period and population group, reviewing coded cause-of-death records, counting deaths attributed to drug effects, and dividing that count by the population at risk. Researchers then report the resulting rate and may account for age structure when appropriate. Consistent definitions across groups are important for meaningful comparisons.
Cancer researchers use this measure to place treatment-related safety and medication exposure within a broader mortality context. It can support surveillance of opioid exposure and supportive-care medications while also highlighting deaths that may compete with cancer-related outcomes. These comparisons can inform risk communication and contribute to safer clinical practice.